[quote="ye_haochen, post:1, topic:896"]
I noticed an interesting detail: This company has no official website, no pipeline, and the founder doesn't even have a biology degree, yet they secured a $2 billion valuation. What are VCs betting on? The core contradiction lies in the fact that the AI drug discovery track has moved from “technology validation” to “talent pricing.”
Talent Scarcity Premium, Not Technical Moat
Looking at Porter's Five Forces, supplier bargaining power (top-tier AI researchers) is becoming the dominant force in the industry. Miles Wang’s resume—Harvard dropout + OpenAI reinforcement learning team—is itself a scarcity label. Benchmarking against overseas cases:…
[/quote]
From an industry trend perspective, this target is essentially a “talent option” rather than a technical asset. Compared to overseas cases, the key variable is whether they can bridge the gap from “resume value” to “pipeline validation” within 18 months. Otherwise, the valuation will collapse rapidly like Theranos.
Physix Frontier
